ASSESSING TECOMA STANS COMPOUNDS AS GLP-1 AGONISTS AND INHIBITORS OF ALPHA-GLUCOSIDASE/ALPHA-AMYLASE
Pakistan Journal of Botany, cilt.57, sa.4, ss.1341-1347, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 57 Sayı: 4
- Basım Tarihi: 2025
- Doi Numarası: 10.30848/pjb2025-4(6)
- Dergi Adı: Pakistan Journal of Botany
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS
- Sayfa Sayıları: ss.1341-1347
- Anahtar Kelimeler: Diabetes mellitus, Hyperglycemia, In silico, Tecoma stans, α-amylase, α-glucosidase
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
The identification of bioactive metabolites in Tecoma stans reveals its biological benefits and traditional uses, particularly in the context of diabetes mellitus. To identify key compounds and assess toxicity risks, ADME-Tox and drug similarity tests were conducted. Ligands identified from the ADME assay were analyzed through In silico molecular docking studies against the GLP-1 receptor, which plays a crucial role in insulin sensitivity, blood sugar regulation, and energy metabolism control. Among the 26 secondary metabolites identified through ADME, the luteolin flavonoid emerged as the most active ligand with a docking score of-6 kcal/mol and a binding energy of-74.76 kcal/mol. Active compounds such as luteolin found in Tecoma stans have been shown to have the potential to treat hyperglycemia through the inhibition of α-glucosidase and α-amylase. The results suggest that the progressive complications of diabetes can be effectively managed.